Evidence map›Paper›PMID 41847327›Full record

ArticleIJTLD open2026

Effectiveness and safety of a shortened oral regimen for rifampicin- or multidrug-resistant TB.

E Herrera-Flores, E Shen, D Vargas-Vasquez, F Llanos-Tejada, Z Ruiz-Vargas, J Cornejo-García, D Vela-Trejo, Z M Puyen-Guerra, M C Rojas, D M Guerra and 11 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

E Herrera-FloresHospital Nacional Arzobispo Loayza, Lima, Peru.
E ShenHarvard Medical School, Boston, MA, USA.
D Vargas-VasquezHospital Nacional Hipolito Unanue, Lima, Peru.
F Llanos-TejadaHospital Nacional Dos de Mayo, Lima, Peru.
Z Ruiz-VargasHospital Nacional Maria Auxiliadora, Lima, Peru.
J Cornejo-GarcíaHospital Nacional Arzobispo Loayza, Lima, Peru.
D Vela-TrejoDirección de Prevención y Control de la Tuberculosis, Lima, Peru.
Z M Puyen-GuerraInstituto Nacional de Salud, Lima, Peru.
M C RojasInstituto Nacional de Salud, Lima, Peru.
D M GuerraSocios en Salud, Lima, Peru.
M L RomoDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
J JimenezSocios en Salud, Lima, Peru.
E OssoDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
L TrevisiDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
A LaHoodDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
M L RichDivision of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
K J SeungDivision of Global Health Equity, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
C D MitnickDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
M F FrankeDepartment of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA.
L LeccaSocios en Salud, Lima, Peru.
V Alarcon-GuizadoDirección de Prevención y Control de la Tuberculosis, Lima, Peru.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) poses significant challenges to patients, providers, and programmes. We evaluated a 9-month, 5-drug all-oral regimen implemented under operational conditions in Peru.

methodsBetween February and September 2023, we enrolled 50 adults with confirmed pulmonary MDR/RR-TB in a prospective observational study conducted within Peru's National Tuberculosis Programme. The regimen consisted of bedaquiline, linezolid, levofloxacin, clofazimine, and delamanid, administered for 9 months and potentially extended to 12 months. We describe the frequency of clinically relevant adverse events of special interest, sputum culture conversion, end-of-treatment outcomes, and changes in dyspnoea and quality of life.

resultsOf 50 participants, 24 (48%) were women, and median age was 28.5 years (interquartile range [IQR]: 23-59 years); 38 (76%) had cavitary disease, and 29 (58%) had bilateral disease. Adverse events were infrequent and manageable; only one case of linezolid-associated myelosuppression led to permanent drug discontinuation. Of 33 participants with positive sputum culture, 100% experienced culture conversion (median: 39 days, IQR: 31-61). Favourable end-of-treatment outcomes were observed in 40 (85.1%) (95% confidence interval: 72.3%-92.6%). Quality-of-life and dyspnoea scores improved significantly in those with treatment success.

conclusionThis 9-month oral regimen was effective and safe and improved patient-reported outcomes. These results support broader adoption in national TB programmes across Latin America and beyond.

Indexed as

adverse eventsculture conversiondyspnoeaextensive TB diseasePeruquality of lifetuberculosis

Identifiers

PMID41847327
PMCPMC12991560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.